Percheron Therapeutics Limited (ASX:PER)

Revenue by Segment

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017	Jun 30, 2016
Unallocated	371.09K	616.18K	384.92K	-	-
Unallocated Growth	-39.77%	60.08%	-	-	-
ATL1102	1.43M	2.35M	1.58M	1.78M	577.76K
ATL1102 Growth	-39.20%	48.88%	-11.14%	207.72%	-11.59%
Total	1.80M	2.97M	1.96M	1.78M	577.76K
Total Growth	-39.32%	51.07%	10.51%	207.72%	-13.59%

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017	Jun 30, 2016
Australia	1.43M	2.35M	1.96M	1.78M	577.76K
Australia Growth	-39.22%	19.74%	10.51%	207.72%	-13.56%
Total	1.43M	2.35M	1.96M	1.78M	577.76K
Total Growth	-39.22%	19.74%	10.51%	207.72%	-13.56%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 16, 2026

Data Sources Report a data error